A 6 Months NIS to Evaluate the Use of Rescue Medication and Quality of Life in Adult Asthmatic Subjects Treated With Symbicort SMART 1-2 Inhalations b.i.d. as Maintenance Therapy Plus Additional Inhalations as-Needed, Compared to Patients Treated With a Free Combination of an Inhaled Glucocorticosteroid and an Inhaled Long Acting beta-2-Agonist Plus as Needed Inhalations of a Short Acting beta-2 Agonist.
Phase of Trial: Phase IV
Latest Information Update: 28 Oct 2015
At a glance
- Drugs Budesonide/formoterol (Primary) ; Beta 2 adrenergic receptor agonists; Corticosteroids
- Indications Asthma
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 02 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Nov 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Oct 2009 Planned number of patients changed from 600 to 500 as reported by ClinicalTrials.gov